Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Scott

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Gastroenterology|November 16, 2005
Macrophage migration inhibitory factor promotes intestinal tumorigenesisJonathan M Wilson, P Louise Coletta, Richard J Cuthbert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
The Lancet. Gastroenterology & Hepatology|October 16, 2018
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysisSami A Chadi, Lee Malcomson, Joie Ensor, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Gastroenterology|November 16, 2005
Macrophage migration inhibitory factor promotes intestinal tumorigenesisJonathan M Wilson, P Louise Coletta, Richard J Cuthbert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
The Lancet. Gastroenterology & Hepatology|October 16, 2018
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysisSami A Chadi, Lee Malcomson, Joie Ensor, et al.
Pageof 5